Sasha Jovanovic
4 min read
NovoCure has seen its share price under pressure in recent years, and the question now is whether the current US$11.72 level makes sense when you line it up against the company’s sales.
-
Over the past 5 years the stock has fallen 89.2%, which puts a sharp spotlight on whether the business performance that produced today’s revenue base can justify the current market value.
-
The recent Not Approvable Letter from the U.S. Food and Drug Administration for Optune Mya raises fresh questions about how quickly NovoCure can translate its tumor treating fields technology into broader sales, and how that timing feeds into what investors are paying for the stock right now.
-
Your read on NovoCure is one view; the desks covering it have another. See what analysts think NovoCure’s shares could be worth.
The issue now is whether NovoCure’s present share price is adequately supported by its sales when measured against the Fair Ratio benchmark.
If NovoCure’s setbacks have you rethinking single-stock exposure, a focused screen of 31 high quality undervalued stocks may provide a broader starting list for valuation-driven research.
Is NovoCure a Bargain on Sales?
P/S works reasonably well for NovoCure because the focus is on commercial traction rather than current earnings. At a P/S ratio of 1.9x, the stock trades below both the Medical Equipment industry average of 2.9x and the peer group on roughly 5.7x. That gap indicates that investors are paying fewer dollars for each dollar of NovoCure revenue compared with a typical sector peer.
The Fair Ratio, which blends factors like growth expectations, profitability profile, size and risk to estimate a more tailored P/S anchor, sits above the current 1.9x P/S. That places NovoCure in undervalued territory on this metric relative to what the framework suggests for a business with its characteristics. Because the recent Not Approvable Letter for Optune Mya clouds part of the product pipeline narrative, the discounted P/S implies the market is already pricing in a fair amount of execution risk. Explore the numbers behind NovoCure’s P/S valuation.
The NovoCure Narrative: What Would Justify Today’s Price?
NovoCure’s valuation question sets up the role of Simply Wall St Narratives, which outline what kind of future growth, margins and earnings path would need to play out for the stock to be worth substantially more or less than today’s price, and they sit on the company’s Community page. Each Narrative treats fair value as a hypothesis about NovoCure’s business that can be revisited over time, rather than a one off snapshot.
